KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Short Term Investments

Last Annual Value

19.93M

3-Year CAGR

%

5-Year CAGR

-39%

10-Year CAGR

-22%

KT

Kalaris Therapeutics Inc Competitors Analysis of Short Term Investments

KLRS · NASDAQ
CompanyShort Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
19.93M
N/A-15.6%N/A 
56.48M
-10.5%N/AN/A
81.31M
51.3%N/AN/A
23.87M
68.4%-33.0%N/A
0.00
N/AN/AN/A
119.08M
-3.0%11.6%N/A
65.04M
44.6%-24.8%N/A
28.42M
-43.8%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
79.95M
-19.5%36.5%11.4%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66